Metabolomic profile of multiple sclerosis patients by means of 1H-NMR analysis
Poster Dec 07, 2015
Federica Murgia1, Lorena Lorefice 2 ,Eleonora Cocco2, Luigi Barberini2, Simone Poddighe1, Maria Rita Murru2, Raffaele Murru2, Jessica Frau2, MD Giuseppe Fenu2, MD, Giancarlo Coghe2, Francesco Del Carratore1, Luigi Atzori1, Maria Giovanna Marrosu3
Introduction: Multiple sclerosis (MS) is a chronic disease characterized by a high level of heterogeneity. Metabolomics is an “-omics” approach with the potential to discover new biomarkers. Thus, we investigated the metabolic profiles of MS patients to define the pathways potentially related to its pathogenesis. Materials and methods: Plasma samples from 73 MS patients and 88 controls (C) were analyzed by 1H-NMR spectroscopy, and followed by multivariate statistical analysis. Results: The model obtained with the OPLS-DA identified predictive metabolic differences between the MS and C (R2X = 0.615, R2Y = 0.619, Q2 = 0.476; p < 0.001). The differential metabolites included glucose, 5-OH-tryptophan, and tryptophan (lower in MS, p < 0.01), and 3-OH-butyrate, acetoacetate, acetone, (higher in MS p < 0.01). The model was evaluated using an external set of samples and the corresponding ROC curve produced (AUC of 0.93). Pathways analysis of the discriminant metabolites was performed and the main metabolic changes could be connected to tryptophan metabolism and energy metabolism. Conclusions: 1H-NMR metabolomic analysis was able to discriminate different metabolic profiles in MS patients compared with HC. The importance of kynurenine (a trypophan derivative), in particular in the immune, response is confirmed. Metabolomics appears to represents a promising non-invasive approach for the study of MS.
We developed an automated sample preparation protocol based on a robotic platform PAL RTC (CTC Analytics AG, Zwingen Switzerland), which represent a modified Bligh and Dyer method producing samples for both hydrophilic metabolomics using GC-MS and lipidomics using SFC-MS simultaneously.READ MORE